Sponsored Links
| Interim Results From Cyclacel Clinical Study Highlight Safety And Efficacy Of Sequential Administration |
 |
 |
 |
| Medical News - Lymphoma and Leukemia | |||
|
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; Cyclacel or the Company), today announced interim results from an ongoing, multicenter, Phase 1/2 clinical trial examining the safety and effectiveness of oral sapacitabine, the Company's lead product candidate, administered sequentially with decitabine. Thirty-day mortality from all causes was 4... Read more: Lymphoma / Leukemia / Myeloma News From Medical News Today
|